摘要
为了能够有效地筛选治疗色素障碍性疾病药物,建立一种转基因斑马鱼药物筛选模型。采用斑马鱼酪氨酸酶相关蛋白1(tyrosinase-related protein 1a,tyrp1a)基因启动子驱动绿色荧光蛋白(green fluorescent protein,GFP),构建出tyrp1a转基因斑马鱼,使绿色荧光能够特异性表达在斑马鱼黑素细胞部位。分别给予斑马鱼促进黑素合成的药物N-苯基硫脲(Nphenylthiourea,PTU)和抑制黑素合成的药物黑素细胞刺激素(alpha-melnaocyte stimulating hormone,α-MSH),检测药物对斑马鱼黑素合成和绿色荧光蛋白表达影响。结果显示,PTU可以抑制斑马鱼黑素细胞黑素合成作用,并且降低转基因斑马鱼绿色荧光蛋白表达。α-MSH可以促进斑马鱼黑素细胞黑素合成作用,并促进转基因斑马鱼绿色荧光蛋白表达。本研究成功地建立了一种新的可以用于色素性障碍疾病药物筛选的转基因斑马鱼模型。
To effectively screen treating pigmentation disorders drug, a new transgenic zebrafish drug screening model was constructed. Green fluorescent protein （GFP） were drived by tyrosinase-related protein la （tyrpla） promoter specific expression in melanocyte. Effect of N-Phenyhhiourea （PTU） and alpha-melanaocyte stimulating hormone （c--MSH） on the GFP expression and melanogenic of tyrpl a： eGFP zebrafish were photographed under the steromicroseope. Results showed that PTU could significantly inhibit the melanogenic and expression of GFP of zebrafish. As compared with control group, α-MSH treatment resulted in marked stimulation of body pigmentation and expression of GFP. In conclusion, a new transgenic zebrafish drug screening model was successfully established, which can be used for treating pigmentation disorders.
出处
《中国药科大学学报》
CAS
CSCD
北大核心
2016年第6期740-743,共4页
Journal of China Pharmaceutical University
基金
国家"重大新药创制"科技重大专项资助项目(No.2011ZX09401-007)
"十二五"国家科技支撑计划资助项目(No.2012BA130B01)~~
